Comment
Author: Admin | 2025-04-28
Respiratory tract congestion, sleep apnea syndrome, wheezingFrequency not reported: Aspiration pneumonia, difficulty breathing, dysphonia, hyperventilation, laryngospasm, pharyngitis, pulmonary embolism, rales, rhinitis, throat tightness[Ref]GenitourinaryEXTENDED RELEASE TABLETS:Common (1% to 10%): Amenorrhea, galactorrhea, urinary tract infectionUncommon (0.1% to 1%): Breast discomfort/pain/tenderness, dysuria, ejaculation disorder, erectile dysfunction, menstrual disorder, pollakiuria, sexual dysfunction, urinary incontinence, urinary retentionRare (0.01% to 0.1%): Breast discharge/engorgement/enlargement, delayed menstruation, priapism, vaginal dischargeFrequency not reported: Breast swelling, irregular menstruation, menstrual disturbances, oligomenorrhea, retrograde ejaculation1-MONTH EXTENDED-RELEASE INJECTABLE SUSPENSION:Common (1% to 10%): Amenorrhea, galactorrhea, urinary tract infectionUncommon (0.1% to 1%): Breast pain, delayed menstruation, dysuria, ejaculation disorder, erectile dysfunction, irregular menstruation, menstrual disorder, pollakiuria, sexual dysfunction, urinary incontinence, vaginal dischargeRare (0.01% to 0.1%): Breast discharge, breast discomfort/engorgement/enlargement, urinary retentionFrequency not reported: Oligomenorrhea, priapism, retrograde ejaculation3-MONTH EXTENDED-RELEASE INJECTABLE SUSPENSION:Common (1% to 10%): Amenorrhea, menstrual disorder, urinary tract infectionUncommon (0.1% to 1%): Breast discomfort/pain, delayed menstruation, dysuria, ejaculation disorder, erectile dysfunction, galactorrhea, pollakiuria, sexual dysfunction, urinary incontinenceRare (0.01% to 0.1%): Breast engorgement/enlargement, urinary retention, vaginal dischargeFrequency not reported: Breast discharge, delayed menstruation, irregular menstruation, oligomenorrhea, priapism, retrograde ejaculation[Ref]Galactorrhea, amenorrhea, and impotence have been reported in patients receiving prolactin-elevating compounds.[Ref]DermatologicEXTENDED RELEASE TABLETS:Common (1% to 10%): Pruritus, rashUncommon (0.1% to 1%): Acne, alopecia, eczema, face edema, urticariaRare (0.01% to 0.1%): Acrodermatitis, cellulitis, dandruff, drug eruption, dry skin, erythema, hyperkeratosis, induration, onychomycosis, seborrheic dermatitis, skin discoloration1-MONTH EXTENDED-RELEASE INJECTABLE SUSPENSION:Common (1% to 10%): Skin lacerationUncommon (0.1% to 1%): Acrodermatitis, acne, alopecia, cellulitis, dry skin, eczema, erythema, face edema, generalized pruritus, induration, onychomycosis, pruritus, rash, subcutaneous abscess, urticariaRare (0.01% to 0.1%): Dandruff, drug eruption, hyperkeratosis, seborrheic dermatitis, skin discolorationFrequency not reported: Papular rashPostmarketing reports: Hyperhidrosis, thrombotic thrombocytopenic purpura3-MONTH EXTENDED-RELEASE INJECTABLE SUSPENSION:Common (1% to 10%): RashUncommon (0.1% to 1%): Acrodermatitis, acne, alopecia, cellulitis, dry skin, eczema, erythema, face edema, induration, onychomycosis, pruritus, urticariaRare (0.01% to 0.1%): Dandruff, drug eruption, hyperkeratosis, subcutaneous abscessFrequency not reported: Generalized pruritus, induration, papular rash, seborrheic dermatitis, skin discolorationPostmarketing reports: Thrombotic thrombocytopenic purpura[Ref]HepaticEXTENDED RELEASE TABLETS:Common (1% to 10%): Increased transaminases (ALT, AST)Uncommon (0.1% to 1%): Gamma-glutamyltransferase increased, increased hepatic enzymesRare (0.01% to 0.1%): Jaundice1-MONTH EXTENDED-RELEASE INJECTABLE SUSPENSION:Common (1% to 10%): Increased transaminases (AST, ALT)Uncommon (0.1% to 1%): Gamma-glutamyltransferase increased, increased hepatic enzymesFrequency not reported: Jaundice3-MONTH EXTENDED-RELEASE INJECTABLE SUSPENSION:Common (1% to 10%): Increased transaminasesUncommon (0.1% to 1%): Gamma-glutamyltransferase increased, increased hepatic enzymesFrequency not reported: Jaundice[Ref]ImmunologicEXTENDED RELEASE TABLETS:Common (1% to 10%): Influenza1-MONTH EXTENDED-RELEASE INJECTABLE SUSPENSION:Common (1% to 10%): Influenza3-MONTH EXTENDED-RELEASE INJECTABLE SUSPENSION:Common (1% to 10%): Influenza[Ref]OcularEXTENDED RELEASE TABLETS:Common (1%
Add Comment